Abstract
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Kristen L. Dalton, MSN, RN, CPNP-AC, CPHON, Meredith R. Johnson, MSN, RN, CRNP-AC
September 16, 2024
Nicole Kuhnly, MS, ACNPC-AG, Jessica Shank Coviello, DNP, APRN, ANP-BC, Catherine A. Kobza, MSN, AGACNP-BC, Et al.
September 16, 2024